PREOPERATIVE PLASMA CONCENTRATION OF MMP-9/TIMP-1 COMPLEXES IS NOT ASSOCIATED WITH DISEASE OUTCOME IN PRIMARY BREAST CANCER (N=483) Anne-Sofie Schrohl.

Slides:



Advertisements
Similar presentations
TOP2A IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN UNSELECTED BREAST CANCER Amit Pancholi Molecular Profiling of Breast Cancer: Predictive Markers of Long.
Advertisements

Oncotype DX® Breast Cancer Assay Clinical Data Review
Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent.
Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.
Neoadjuvant Chemotherapy in Malignant Peripheral Nerve Sheath Tumors Elizabeth Shurell, M.D., M.Phil. UCLA General Surgery Resident Research Fellow, Division.
Sino-Danish Breast Cancer Research Centre Beijing Genomic Institute, Shenzhen University of Copenhagen University of Århus University of Southern Denmark.
Carolina Breast Cancer Study: Breast cancer subtypes and race Robert Millikan University of North Carolina Chapel Hill, NC.
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
Meta-analysis of trials of radiotherapy in DCIS Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
A Propensity-matched Study of Lobectomy Versus Segmentectomy for Radiologically Pure Solid Small-sized Non-small Cell Lung Cancer Terumoto Koike 1, Seijiro.
Introduction MarkerPolymorphisms in CYP2C19 (*2 and *17) assessed by Taqman allelic discrimination ObjectivesTo evaluate the predictive capacity of CYP2C19.
THE SIGNIFICANCE OF HISTOLOGICAL SUBSTAGING IN CURATIVE RESECTED T3 COLORECTAL CANCER Karl Mrak & Jörg Tschmelitsch Department of Surgery, Barmherzige.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2014.
Tang G et al. Proc SABCS 2010;Abstract S4-9.
HERA: KEY DESIGN ELEMENTS, RESULTS AND FUTURE PLANS NSABP 17 SEPTEMBER 2005 Brian Leyland-Jones Minda De Gunzberg Professor of Oncology, McGill University,
A 14-gene prognosis signature predicts metastasis risk in node-negative, estrogen receptor-positive, Tamoxifen-treated breast cancer in different ethnogeographic.
Appendix Supplementary data (online only) to: Marleen Kok, Wilbert Zwart, Caroline Holm, Renske Fles, Michael Hauptmann, Laura J. Van ’t Veer, Lodewyk.
©2013 Astute Medical, Inc. PN 0138 Rev B 2013/03/19
Supplemental Figures Loss of circadian clock gene expression is associated with tumor progression in breast cancer Cristina Cadenas 1*, Leonie van de Sandt.
Sgroi DC et al. Proc SABCS 2012;Abstract S1-9.
Metabolic Syndrome and Recurrence within the 21-Gene Recurrence Score Assay Risk Categories in Lymph Node Negative Breast Cancer Lakhani A et al. Proc.
Dubsky P et al. Proc SABCS 2012;Abstract S4-3.
Validity of more than 30Gy radiation therapy for long-surviving patients with painful bone metastases E.Katayama 1,2, H.Okada 1, I.Asakawa 2, T.Tamamoto.
Guanylyl Cyclase C (GCC) Lymph Nodes (LN) Classification as a Prognostic Marker in Patients with Stage II Colon Cancer: A Pooled Analysis Daniel J. Sargent,
INCREASED EXPRESSION OF PROTEIN KINASE CK2  SUBUNIT IN HUMAN GASTRIC CARCINOMA Kai-Yuan Lin 1 and Yih-Huei Uen 1,2,3 1 Department of Medical Research,
1789 patients, 1982 – 1989, premenopausal, node + or Tumor > 5cm, M0 Total mastectomy, level I + II (partly) + CMF +/- 50Gy/25fx (electrons + photons)
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
Start or Switch?: Latest data from ABCSG/ARNO
Clinical variables, pathological factors, and molecular markers for enhanced soft tissue sarcoma prognostication G. Lahat, B. Wang, D. Tuvin, DA. Anaya,
Outcome of chemotherapy in synovial sarcoma (sys) patients (pts): review of 15 clinical trials from EORTCc involving advanced sys compared to other Soft.
Ductal Carcinoma in Situ with Microinvasion: Prognostic Implications, Long-term Outcomes, and Role of Axillary Evaluation Rahul R. Parikh, MD 1, Bruce.
Snyder D, Heidel RE, Panella T, Bell J, Orucevic A University of Tennessee Medical Center – Knoxville Departments of Pathology, Surgery, and Medicine BREAST.
Poster Title ABSTRACT #59 Cell cycle progression genes differentiate indolent from aggressive prostate cancer. Steven Stone 1 Jack Cuzick 2, Julia Reid.
Serum Levels of Glycosaminoglycans (GAGs) and Insulin Like Growth Factor-1 (IGF-1) as New Diagnostic Markers for Hepatocellular Carcinoma. Ahmad S. Ibrahim*,
1 Lecture 6: Descriptive follow-up studies Natural history of disease and prognosis Survival analysis: Kaplan-Meier survival curves Cox proportional hazards.
Tumor clock protein PER2 as a determinant of survival in patients (pts) receiving oxaliplatin-5-FU- leucovorin as 1st line chemotherapy for metastatic.
CHFR METHYLATION AS AN EPIGENETIC MARKER FOR RECURRENCE OF COLON CANCER M. D. Anderson Cancer Center, Houston, Texas Motofumi Tanaka, Salil Sethi, Donghui.
Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,
Extended adjuvant treatment with anastrozole: results from the ABCSG Trial 6a R Jakesz, H Samonigg, R Greil, M Gnant, M Schmid, W Kwasny, E Kubista, B.
FREEDOM FROM PROGRESSION FOR PATIENTS RECEIVING I 125 VERSUS Pd 103 FOR PROSTATE BRACHYTHERAPY Jane Cho, Carol Morgenstern, Barbara Napolitano, Lee Richstone,
Table 1. Characteristics of patients and the results of the log-rank test of prognostic factors Median (range) No. of patients No. of CRPC Median progression.
14 th Annual Meeting of the Connective Tissue Oncology Society November 13-15, 2008, London, UK Oliver Zivanovic, Mario M. Leitao, Alexia Iasonos, Lindsay.
S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.
Identification of localized rectal cancer (RC) patients (pts) who may NOT require preoperative (preop) chemoradiation (CRT). D. Roda 1, M. Frasson 2, E.
Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Gene Expression Signatures, Clinicopathological Features,
What Factors Predict Outcome At Relapse After Previous Esophagectomy And Adjuvant Therapy in High-Risk Esophageal Cancer? Edward Yu 1, Patricia Tai 5,
R3 정수웅 / Prof. 김시영 This article was published on September 28, 2015, at NEJM.org. DOI: /NEJMoa Prospective Validation of a 21-Gene Expression.
Univariate Analyses Treatment Outcome And Patterns Of Relapse Following Adjuvant Carboplatin For Stage I Testicular Seminoma: Results From a 17 Year UK.
Neuropathy Is Not Associated With Clinical Outcomes in Patients Receiving Adjuvant Taxane-Containing Therapy for Operable Breast Cancer Bryan P. Schneider,
COMPARING DISEASE OUTCOME OF WOMEN WITH HORMONE RECEPTOR NEGATIVE/HER2 POSITIVE (HR-/HER2+) OR TRIPLE NEGATIVE (TN) METASTATIC BREAST CANCER (MBC) RECEIVING.
Evaluating the Clinical Outcomes of Sixty-Three Patients Treated with Gamma Knife as Salvage Therapy for Glioblastoma Multiforme Erik W Larson, Halloran.
J Clin Oncol 30: R2 윤경한 / Prof. 김시영 Huan Jin, Dongsheng Tu, Naiqing Zhao, Lois E. Shepherd, and Paul E. Goss.
Mamounas EP et al. Proc SABCS 2012;Abstract S1-10.
CCO Independent Conference Highlights
CCO Independent Conference Highlights
Phase III SOLE: Continuous vs Intermittent Extended Letrozole After Adjuvant Endocrine Therapy in Early HR+ Breast Cancer CCO Independent Conference Highlights*
Prognostic significance of tumor subtypes in male breast cancer:
Immunoscore Prognostic in Colon Cancer
Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal Women with Node-Positive, Estrogen- Receptor-Positive Breast Cancer.
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
ESPAC-4: Adjuvant Gemcitabine/ Capecitabine Improves 5-Yr Survival vs Gemcitabine Alone in Resected Pancreatic Ductal Carcinoma CCO Independent Conference.
EMT inducing transcription factor SIP1: a predictive biomarker of colorectal cancer survival and recurrence? A Patel, R Sreekumar, R Bhome, KA Moutasim,
Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results.
Untch M et al. Proc SABCS 2010;Abstract P
Effect of Obesity on Prognosis after Early Breast Cancer
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
Badwe RA et al. SABCS 2009;Abstract 72.
High CDK6 expression predicts poor prognosis in EOC patients
ADAM8 is overexpressed in human breast cancer AADAM8 mRNA expression in samples from breast tumor and normal breast tissue was analyzed using the Oncomine.
Presentation transcript:

PREOPERATIVE PLASMA CONCENTRATION OF MMP-9/TIMP-1 COMPLEXES IS NOT ASSOCIATED WITH DISEASE OUTCOME IN PRIMARY BREAST CANCER (N=483) Anne-Sofie Schrohl 1, Sidse Ørnbjerg Würtz 1, Susanne Møller 2, Birgitte Sander Nielsen 1, Henning T. Mouridsen 2, and Nils Brünner 1 1 University of Copenhagen, Faculty of Life Sciences & Sino-Danish Breast Cancer Research Centre, Copenhagen, Denmark 2 Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark Contact: RESULTS ASSAY AND SAMPLES AIM & HYPOTHESIS Plasma MMP-9/TIMP- 1 complex levels were not associated with age, lymph node status, steroid hormone receptor status, or tumor size. Significant associations with tumor grade (p=0.04) and menopausal status (p=0.001) were found. Table 1. Patient and tumor characteristics and association with MMP-9/TIMP-1 complexes Characteristic All patients (N=483) MMP-9/TIMP-1 P (Χ 2 -test) Q1-25 (%) Q25-50 (%) Q50-75 (%) Q (%) Age ≤ 50 years years ≥ 70 years Lymph node status Positive Negative Hormone rec. status Positive Negative Unknown Tumor size 0-20 mm > 20 mm Tumor grade Grade 1 Grade 2 and 3 Unknown Menopausal status Premenopausal Postmenopausal CONCLUSIONS ACKNOWLEDGEMENTS VariableHazard ratio95% CIP MMP-9/TIMP-1 complex Q25-50 vs. Q1-25 Q50-75 vs. Q1-25 Q vs. Q Age years vs. < 50 years ≥ 70 years vs. < 50 years < Lymph node status Positive vs. negative Hormone rec. status Positive vs. negative Tumor size > 20 mm vs mm Tumor grade Grade 2 and 3 vs. grade Menopausal status Post- vs. premenopausal Only age ≥ 70 years and steroid hormone receptor status contributed significantly to the multivariable model. MMP-9/TIMP-1 complex levels were not associated with recurrence-free survival. Table 2. Multivariable Cox proportional hazards model of recurrence-free survival Figure 1. Recurrence-free survival of patients grouped in quartiles by plasma MMP- 9/TIMP-1 level Plasma levels of MMP-9/TIMP-1 complexes were not associated with recurrence-free survival (logrank test p=0.9565). Proportion alive without recurrence  No association was found between plasma concentration of MMP-9/TIMP-1 complexes and disease outcome  These results suggest that other fractions of MMP-9 and TIMP-1 carry prognostic information, e.g. free MMP-9 and TIMP-1 or MMP-9 and TIMP-1 bound to other plasma proteins This work was supported by The Danish Cancer Society Anne-Sofie Schrohl is supported by the Danish Council for Independent Research | Medical Sciences Both Matrix Metalloproteinase-9 (MMP-9) and Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) are associated with a poor prognosis in breast cancer. Here, our aim was to measure the concentration of MMP-9/TIMP-1 complexes in plasma from primary breast cancer patients and to evaluate whether these levels are associated with disease outcome. The hypothesis was that high plasma levels of MMP-9/TIMP-1 complexes are associated with increased recurrence risk in primary breast cancer patients. MMP-9/TIMP-1 COMPLEX ELISA The human MMP-9/TIMP-1 Complex DuoSet® ELISA Development System (R&D Systems, Inc.) was validated for measurement of MMP-9/TIMP-1 complex levels in human plasma. The validation process included investigation of reproducibility (intra-assay, inter-assay), recovery, and linearity upon dilution of samples. PLASMA SAMPLES Preoperative EDTA plasma samples from 483 consecutively enrolled primary breast cancer patients were analyzed. Prior to analysis, samples were diluted in reagent diluent as recommended by the manufacturer (1:3). The median MMP-9/TIMP-1 complex concentration was 2.06 ng/mL (range, >14.8 ng/mL). DATA ANALYSIS The possible associations between MMP-9/TIMP-1 plasma level and patient- and tumor characteristics were analyzed using a Χ 2 test. The possible association with recurrence-free survival was investigated using a logrank test and a multivariable Cox proportional hazards model. In the analyses, patients were grouped in quartiles based on their plasma MMP-9/TIMP-1 complex level. Recurrence-free survival was defined as survival without breast cancer relapse, contralateral breast cancer, other malignant disease and death without a previous relapse. REFERENCES Li H. et al (2004). “Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node- negative breast carcinoma.” Breast Cancer Res Treat 88: Somiari S.B. et al (2006). “Circulating MMP2 and MMP9 in breast cancer – Potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories.” Int J Cancer 119: Würtz S.Ø. et al (2008). “Plasma and serum levels of tissue inhibitor of metalloproteinases-1 are associated with prognosis in node-negative breast cancer: a prospective study.” Mol Cell Proteomics 7(2):